30/10/2020 (Agence Europe) – Novartis will soon be able to market its treatment to prevent vaso-occlusive seizures in patients with sickle cell disease (a genetic disorder also known as sickle cell anaemia). The Swiss pharmaceutical group announced on Friday 30 October that it had received the green light from the European Commission for Adakveo, also known as crizanlizumab. The Commission thus followed the favourable opinion given in July by the Committee for Medicinal Products for...